Bio-Works Technologies AB (BIOWKS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bio-Works Technologies AB (BIOWKS) has a cash flow conversion efficiency ratio of -0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.17 Million ≈ $-449.08K USD) by net assets (Skr49.21 Million ≈ $5.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIOWKS equity to assets ratio to measure how much of total assets are equity-financed.
Bio-Works Technologies AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Bio-Works Technologies AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BIOWKS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Bio-Works Technologies AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio-Works Technologies AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pyung Hwa Hldg
KO:010770
|
0.224x |
|
Industrial Investment Trust Limited
NSE:IITL
|
0.148x |
|
Mudajaya Group Bhd
KLSE:5085
|
-0.012x |
|
Communication & System Solution Public Company Limited
BK:CSS
|
0.010x |
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
0.014x |
|
CHUNGDAHM Learning Inc
KQ:096240
|
-0.110x |
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
-0.276x |
|
FibroGen Inc
NASDAQ:FGEN
|
-0.106x |
Annual Cash Flow Conversion Efficiency for Bio-Works Technologies AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Bio-Works Technologies AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see BIOWKS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr49.21 Million ≈ $5.30 Million |
Skr-18.81 Million ≈ $-2.02 Million |
-0.382x | +60.52% |
| 2024-12-31 | Skr44.58 Million ≈ $4.80 Million |
Skr-43.17 Million ≈ $-4.65 Million |
-0.968x | +27.73% |
| 2023-12-31 | Skr44.03 Million ≈ $4.74 Million |
Skr-58.99 Million ≈ $-6.35 Million |
-1.340x | -127.40% |
| 2022-12-31 | Skr67.69 Million ≈ $7.28 Million |
Skr-39.88 Million ≈ $-4.29 Million |
-0.589x | -378.17% |
| 2021-12-31 | Skr108.51 Million ≈ $11.68 Million |
Skr-13.37 Million ≈ $-1.44 Million |
-0.123x | +89.36% |
| 2020-12-31 | Skr37.46 Million ≈ $4.03 Million |
Skr-43.36 Million ≈ $-4.67 Million |
-1.158x | -137.44% |
| 2019-12-31 | Skr82.13 Million ≈ $8.84 Million |
Skr-40.04 Million ≈ $-4.31 Million |
-0.488x | +13.37% |
| 2018-12-31 | Skr61.64 Million ≈ $6.63 Million |
Skr-34.69 Million ≈ $-3.73 Million |
-0.563x | -163.23% |
| 2017-12-31 | Skr99.32 Million ≈ $10.69 Million |
Skr-21.23 Million ≈ $-2.28 Million |
-0.214x | +65.04% |
| 2016-12-31 | Skr23.64 Million ≈ $2.54 Million |
Skr-14.46 Million ≈ $-1.56 Million |
-0.612x | -4.42% |
| 2015-12-31 | Skr22.41 Million ≈ $2.41 Million |
Skr-13.12 Million ≈ $-1.41 Million |
-0.586x | -- |
About Bio-Works Technologies AB
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chr… Read more